GE HealthCare Technologies (GEHC)
Salud / Equipamiento y diagnóstico médico
Global manufacturer of medical technology (imaging, pharmaceutical diagnostics, and patient monitoring) spun off from GE in 2023, with a record backlog of $23.9bn and organic orders +11.1%. At $74 (18× normalized earnings), with earnings still depressed by peak 2025 tariff impact and margin recovery already guided by management, base 5a $131 (+12%/year price, +12% with dividend): Undervalued.
- Price
- $74.03
- Intrinsic value (5y, base)
- $131
- Total annual return (5y)
- 12.3%
- Status (nominal)
- Undervalued
- Margin of safety
- +30%
The essentials
- Leading manufacturer of medical technology—imaging (CT, MRI, ultrasound), pharmaceutical diagnostics (contrast agents, radiopharmaceuticals), and patient monitoring—with nearly 130 years of history and a global installed base supporting recurring service and consumables revenue. Record backlog of $23.9bn and organic orders +11.1% in Q2 2026.
- TTM earnings are depressed by peak 2025 tariff impact (~$245M to operating income, ~$285M to cash flow) before IEEPA refunds recognized only in Q2 2026; reaffirmed guidance points to adjusted EBIT margin of 15.4-15.7% for 2026, a recovery already underway that market price does not fully reflect.
- The drag is Patient Care Solutions (patient monitoring/cardiology), in persistent decline (-1.5% organic FY2025, negative margin in Q2 2026) and under strategic review that could lead to divestiture. The moat—unique combination of imaging plus pharmaceutical diagnostics plus global service network—is stable but not immune to independent service organizations' pressure.
Intrinsic value — two valuation methods
Total return at 5 years: 12.3%/year = 12.1% appreciation + 0.2% dividend. The target price ($131) is ex-dividend; the $1 in dividends collected over 5 years are added separately.
By both methods, the value today (DCF $112 · Multiples $106) exceeds the market price ($74).
Pillars of the analysis
The verdict — today vs 5 years
Today — fairly valued: at $74 trades ~30.1% below its value discounted to today (~$106); the discount is positive but does not reach the margin of safety we require (≥38%).
At 5 years — Infravalorado: the target price ($131) plus dividends yield above the required average return (10%) — the business compounds.
The bridge: the return at 5 years exceeds the risk-free rate (4.5%) — but the discount does not reach the required margin of safety (≥38%). To require a 15% annual return, it would need to be bought at ~$66.
Thesis
The business
GE HealthCare is a global medical technology manufacturer of moderate-to-high quality: unique combination of imaging equipment and pharmaceutical diagnostics, extensive installed base with recurring service revenue, and a record backlog ($23.9bn, book-to-bill 1.15×) anticipating acceleration. The drag is Patient Care Solutions, in decline and under strategic review.
Valuation
A single-segment medical technology manufacturer is valued by P/E on normalized net income. At $74 GEHC trades at 18× earnings, but that TTM earnings are depressed by peak 2025 tariff impact.
Base case anchors year 1 at the midpoint of guidance reaffirmed 29-Jul-2026 (organic revenue +3.5%, adjusted EPS ~$4.94, normalized margin ~10.4%) and from there revenue accelerates to +6.0% by year 5 (sustained by record backlog) with margin expanding to 12.5%, and multiple compressing from 18× toward 18×. That gives $131/share in five years → price CAGR +12%; with dividend, +12% total.
Margin of safety
It trades at a real discount to value, though short of the required margin of safety. Total return +12% emerges mostly from normalization of earnings today depressed by a tariff impact already recognized and under way to reverse per management's own guidance—not from aggressive structural growth assumption. The verdict is Undervalued.
What to watch
Central disconfirmer: guided margin recovery (adjusted EBIT 15.4-15.7% for 2026) does not materialize—from persistent tariffs/input inflation or deeper Patient Care Solutions contraction. Also monitor conversion of record backlog to reported revenue and outcome of Patient Care Solutions strategic review.
Educational / informational. Does not constitute investment advice.